1.. Introduction {#S1}
================

Hematopoietic stem cell transplantation (HSCT) can provide full hematopoietic reconstitution after myeloablative therapy commonly used to treat hematologic malignancies, solid tumors, or immunemediated bone marrow (BM) failure diseases, such as aplastic anemia ([@R13]; [@R42]; [@R14]). Graft-versus-host disease (GvHD) develops when immune-competent cells in the stem cell graft are activated and damage host tissues ([@R51]). Affecting up to 80% of allogeneic HSCT recipients ([@R19]), GvHD remains a significant barrier to the broader use of HSCT in the clinic.

T cells contribute prominently to GvHD pathophysiology. Skin, gut, and liver are major organs targeted by T cells during GvHD, but damage to hematopoietic tissues also occurs ([@R41]). T cells are activated by antigen-specific signals delivered through the T cell receptor, coupled with antigen non-specific signals conveyed through CD28 co-stimulatory receptors. The T cell-specific kinase, Protein Kinase C theta (PKCθ), is phosphorylated on multiple residues, downstream of CD28 signaling. Functional PKCθ is essential for mediating GvHD responses ([@R57]), including through its nuclear regulation of pro-inflammatory gene expression ([@R52]). Reducing PKCθ activity in alloreactive T cells; therefore, constitutes an attractive approach to limiting GvHD.

Strategies to prevent or treat GvHD include prophylactic or therapeutic administration of immunosuppressive agents, such as cyclosporine, although prognosis is poor for patients who progress to a steroid-refractory state ([@R59]). More recently, MSC-based therapies are being rigorously investigated. While administering MSCs for steroid-refractory GvHD is promising ([@R16]), there remains a critical need both for more effective treatments for acute GvHD, in general, and for improving the performance of MSC-based therapies, specifically.

Induced pluripotent stem cells (iPSCs) can proliferate almost indefinitely without losing pluripotency, making it feasible to generate a nearly limitless supply of iPSCs from a single blood or tissue donation ([@R27]). Harnessing the expansion potential of iPSCs prior to differentiation, allows for producing vast numbers of iPSC-derived MSCs, without excessively expanding the MSCs themselves. This enables ongoing production of commercial quantities of minimally-expanded MSCs from a single iPSC line.

Here we report on the characterization and pre-clinical efficacy of the Cymerus™ MSCs, derived from iPSCs through the mesenchy-moangioblast pathway ([@R58]). Immunophenotyping and in vitro functional studies show iPSC-MSCs exhibit a typical MSC phenotype and a normal karyotype. Using a humanized mouse model of GvHD, we demonstrate single- or dual-dose infusions of iPSC-MSCs, given under therapeutically relevant conditions, attenuate GvHD severity and provide a significant survival benefit. We demonstrate that the immunosuppressive effects of iPSC-MSCs result from their modulating PKCθ phosphorylation and cellular localization in T cells. Finally, we show a reduced expression of pro-inflammatory molecules correlate highly with clinical response to iPSC-MSC administration, suggesting these may serve as biomarkers to monitor therapeutic response.

2.. Materials and methods {#S2}
=========================

2.1.. Animals {#S3}
-------------

Animal studies were approved by the Institutional Animal Care and Use Committee, University of Massachusetts Amherst. Six-weeks-old female NOD.Cg-*Prkdc*^*scid*^ *Il2rg*^*tm1Wjl*^/SzJ (NSG) mice, were purchased from Jackson Laboratories (Bar Harbor, ME). Mice were rested for one week prior to use and housed under pathogen-free conditions in microisolator cages with acidified, antibiotic water throughout the experimental procedures.

2.2.. iPSC-MSC derivation {#S4}
-------------------------

The iPSCs used to generate CYP-001 were manufactured on Cynata's behalf by Cellular Dynamics International, Inc. (Madison, WI). The iPSCs were derived from CD34-enriched peripheral blood mononuclear cells using an episomal plasmid-based, transgene-free, viral-free and feeder layer-free reprogramming procedure. Manufacture of the iPSC-MSCs commenced with the expansion of iPSCs in Essential-8™ Complete Medium and standard plastic tissue culture dishes coated with recombinant vitronectin. The expanded iPSCs were harvested as single cells and plated on 6-well plates coated with Collagen IV, and the medium changed to differentiation medium (Iscove's modified Dulbeccos Medium) supplemented with Ham's F-12 Nutrient Mix, BMP-4, and Activin A. The cells were subsequently transferred to semi-solid mesenchymal-Colony Forming Medium containing Stem-Span™ Serum Free Expansion Medium, ES-Cult™ M3120, Human Endothelial Serum-Free Medium (ESFM), and human fibroblast growth factor-2 (FGF-2). Cells were incubated until spherical mesenchymoangioblast colonies formed. The resulting colonies were harvested using a 100 μM strainer and resupended in Mesenchymal Serum-Free Expansion Medium containing StemLine II, Human ESFM, and FGF-2, grown in adherent culture on fibronectin/collagen-coated flasks. The final harvested iPSC-MSCs were cryopreserved and stored in the vapor phase of liquid nitrogen until use.

2.3.. Assessing IDO and PD-L1 expression by IFNγ-licensed iPSC-MSCs {#S5}
-------------------------------------------------------------------

iPSC-MSCs were seeded on fibronectin- and collagen-coated plates. The next day they were licensed with 50 ng/mL of Recombinant Human IFNγ (BioLegend, San Diego, CA) for 24 and 48 h in M-SFEM, at 37 °C in 5% CO~2~. Cells were split and treated as follows: RNA was isolated using the QuickRNA miniprep kit (Zymo Research, Irvine, CA) and qPCR was performed using the SYBR Green Master Mix (BioTools, Jupiter, FL) to assess indoleamine 2,3-dioxygenase (IDO) mRNA levels. β-Actin was the reference gene used for normalization. Cells were also stained with antibodies specific for surface markers, as indicated. Data were acquired on a BD LSR Fortessa Flow Cytometer (Becton Dickinson, Franklin Lakes, NJ) and analyzed using FlowJo (version 10.0, Treestar, Ashland, OR).

2.4.. iPSC-MSC labeling and in vivo trafficking {#S6}
-----------------------------------------------

For cell labeling, iPSC-derived MSCs and BM-MSCs were labeled using Celsense (Pittsburgh, PA) ^19^F reagents, under Celsense protocols. Nuclear Magnetic Resonance (NMR) analysis was performed to confirm ^19^F integration into the cells. For ex vivo tissue detection confirmation, three animals each were dosed through the tail vein with low (8 × 10^5^) or high (3 × 10^6^) doses of ^19^F-labeled iPSC-MSCs or low or high doses of BM-MSCs. After 24 h, animals were sacrificed, and selected tissues were harvested. Tissues were analyzed for the presence of cells by both NMR and immunohistochemistry, to confirm that ^19^F signals were representative of the cells' location. Alexa Fluor® 488 dual fluorescent tag (ThermoFisher Scientific, Waltham, MA) and STEM101 mouse monoclonal antibody specific for the human cell nucleus marker, Ku80 (StemCells, Newark, CA) were used to facilitate IHC. Some animals were followed up to 28 days for long-term biodistribution studies, *in vivo*, of labeled cells.

2.5.. Graft-vs-host disease induction {#S7}
-------------------------------------

Human PBMCs (StemCell Technologies, Vancouver, BC, Canada) were thawed and rested overnight at 37 °C in 5% CO~2~. NSG mice were conditioned with 2 Gy of total body irradiation from a ^137^Cs source, then rested for 4 h. PBMCs were washed with sterile PBS and 10 × 10^6^ cells in 150 μL of sterile PBS were delivered to NSG mice *via* the tail vein.

2.6.. iPSC-MSC administration {#S8}
-----------------------------

iPSC-MSCs were thawed at 37 °C, washed in sterile PBS, 2 × 10^6^ cells/mL were resuspended in 150 μL sterile PBS. For single- and dual-dose treatments, 2 × 10^6^ iPSC-MSCs were administered into NSG mice *via* tail vein injection on day +14 only, or on days +14 and +18, respectively, after GvHD induction.

2.7.. Biomarker analysis {#S9}
------------------------

BM, spleen, and peripheral blood were collected on day +19 to determine percent PBMCs \[positive human CD45 cells % / (positive human CD45 cells % + positive mouse CD45 cells %)\] and infiltration of human CD4 and CD8 T cells. Human CD4 and CD8 T cells were stained with antibodies specific for CD25, pPKCθ (Thr538), NOTCH1, and T-BET. Data were acquired on a BD LSR Fortessa Flow Cytometer (Becton Dickinson) and analyzed using FACSDiva Software (version 8.0, Becton Dickinson) and FlowJo (version 10.0, Treestar).

2.8.. LEGENDPlex™ Bead-based immunoassay {#S10}
----------------------------------------

Peripheral blood for cytokine analysis was obtained on day +19 from animals via cardiac puncture, immediately following humane euthanasia. The LEGENDPlex™ Human Th1/Th2 panel (8-plex; BioLegend) was used to determine IFNγ. Data were acquired on a BD LSR Fortessa Flow Cytometer (Becton Dickinson) and analyzed using LEGENDPlex™ Software, Version 7.0 (BioLegend).

2.9.. Protein subcellular localization {#S11}
--------------------------------------

BM, spleen, and peripheral blood were collected on day +19. Single cell suspensions were prepared and surface stained for CD4 and CD8 T cells. Samples were fixed and permeabilized using the Foxp3 Staining Buffer Kit (BD Biosciences) and stained with fluorescently-conjugated antibodies specific for pPKCθ (Thr538), NOTCH1, and T-BET. Nuclei were stained using cell-permeable DRAQ5™ Fluorescent Probe (ThermoFisher Scientific). Cells were visualized and quantified using an ImageStream®^X^ Mark II Imaging Flow Cytometer (EMD Millipore, Billerica, MA). Subcellular localization of pPKCθ (Thr538), NOTCH1, and T-BET were determined using the Nuclear Localization Wizard, IDEAS® Software, upon masking of nuclear and non-nuclear regions to quantify proteins localized in and out of the nucleus.

2.10.. Statistical analyses {#S12}
---------------------------

Data are the mean ± SEM; all *in vitro* experiments were repeated at least three times. Unpaired, two-tailed Student's *t*-test using (Prism5; GraphPad Software, San Diego, CA) was used for statistical comparison of two groups, with Welch's correction applied when variances were significantly different. Two-way ANOVA (Prism 5; GraphPad Software) was used for the comparison of variables, which are influenced by two different categories and followed by Bonferroni post-test. For *in vivo* experiments, survival benefit was determined using Kaplan--Meier analysis with an applied log-rank test. P values of ≤0.05 were considered significantly different.

3.. Results {#S13}
===========

3.1.. iPSC-derived MSCs phenotypically resemble native MSCs, respond to IFNγ licensing, and dampen PBMC activation potential {#S14}
----------------------------------------------------------------------------------------------------------------------------

MSCs are identified by a constellation of criteria: adherence to the tissue culture dish, tri-lineage differentiation potential, and expression of several distinct surface markers together with the absence of others ([@R15]). MSCs also acquire immunosuppressive functions following exposure to pro-inflammatory cytokines, such as interferon gamma (IFNγ); a process referred to as IFNγ-licensing.

Cymerus™ iPSC-MSCs were derived from CD34-enriched peripheral blood mononuclear cells using an episomal plasmid-based, transgene-free, viral-free, feeder-layer-free process, prior to differentiating and expanding in culture ([Supplemental Fig. S1](#SD1){ref-type="supplementary-material"}). iPSCs are pluripotent and possess indefinite growth potential. This characteristic makes them especially attractive for in vitro expansion, without undergoing senescence, prior to differentiation. However, this intrinsic growth potential may also predispose these cells to genetic instability and putative tumor formation. Therefore, we examined the genetic stability of the iPSC-MSCs by karyotyping. As shown in [Supplemental Fig. S2](#SD3){ref-type="supplementary-material"}, we confirmed that the iPSC-MSCs we generated for use in this study are genetically stable, with no clonal abnormalities detected at the applied band resolution of 400--450 bands.

We further characterized the fully-differentiated iPSC-MSCs by examining their surface markers and whether their expression changed after exposure to IFNγ. We found that molecules expressed on iPSC-MSCs are consistent with an MSC phenotype ([Supplemental Fig. S3 A](#SD4){ref-type="supplementary-material"}--[I](#SD4){ref-type="supplementary-material"}). iPSC-MSCs exhibit tri-lineage differentiation ([Supplemental Fig. S4 A](#SD5){ref-type="supplementary-material"}--[C](#SD5){ref-type="supplementary-material"}), also in agreement with their characterization as MSCs ([@R43]). We assessed post-thaw senescence of iPSC-MSCs, because replicative senescence in cryopreserved cells, following ex vivo expansion, may reduce *in vivo* potency ([@R18]; [@R55]; [@R60]). Our results suggest that up to one week following cell thawing, iPSC-MSCs cultured *in vitro* do not exhibit signs of functional senescence, as measured by β-galactosidase staining ([Supplemental Fig. S4 D](#SD5){ref-type="supplementary-material"}).

In response to IFNγ exposure, native MSCs can acquire immunosuppressive capabilities. MSCs use two well-characterized mechanisms to curtail immune cell activation: through the Programmed Cell Death Protein (PD)-1-Programmed Cell Death Protein-Ligand (PD-L)1 signaling axis ([@R62]) and through immune-modulating indoleamine 2,3-dioxygenase (IDO; [@R49]). MSCs licensed by IFNγ upregulate and can secrete soluble PD-L1, an immune checkpoint inhibitor ([@R12]). We found that iPSC-MSCs express moderate amounts of PD-L1 that were further increased in response to IFNγ ([Fig. 1A](#F1){ref-type="fig"}). At the protein level, intracellular IDO in IFNγ-licensed iPSC-MSCs, increased approximately 3-fold over baseline expression after 24 h of exposure to IFNγ, and nearly 5-fold after 48 h in culture with IFNγ ([Fig. 1B](#F1){ref-type="fig"}). We noted very high *IDO* transcript levels in iPSC-MSCs cultured in the presence of IFNγ for 24 h, which increased further after 48 h of IFNγ exposure ([Fig. 1C](#F1){ref-type="fig"}).

We next evaluated what effects iPSC-MSCs have on human T cell proliferation and differentiation potential *in vitro*. We determined the suppressive capacity of the iPSC-MSCs using a previously-described immunopotency assay ([@R5]). A normalized immunopotency assay value (IPA~v~) was calculated by dividing the IPA~v~ of each sample by the IPA~v~ of the reference standard. This allowed us to compare the level of suppression conveyed by each sample relative to the reference standard. The IPA~v~ for products used in this study ([Supplemental Table S1](#SD11){ref-type="supplementary-material"}) indicates that iPSC-MSCs provide a modest suppressive effect on CD4 T cell proliferation during *in vitro* co-culture.

After antigenic stimulation, human PBMCs upregulate signaling molecules that further facilitate their activation and differentiation potential. These include the high-affinity subunit of the IL-2 receptor, CD25, the transmembrane receptor, NOTCH1, the master transcriptional regulator of T helper type1 (Th1) cells, T-BET (T-box expressed in T cells), and the pro-inflammatory cytokine, IFNγ ([@R36]; [@R34]). Compared to PBMCs cultured alone, coculturing PBMCs with iPSC-MSCs significantly reduced the percentage of cells expressing T-BET ([Fig. 1D](#F1){ref-type="fig"}) and IFNγ ([Fig. 1E](#F1){ref-type="fig"}), suggesting iPSC-MSCs reduce the potential of activated T cells to adopt a Th1 cell fate. The amount of T-BET or IFNγ produced on a per cell basis was also lower in PBMCs co-cultured with iPSC-MSCs ([Fig. 1D](#F1){ref-type="fig"}, [E](#F1){ref-type="fig"}, respectively), although this downward trend did not reach statistical significance during the short culture period. Co-culturing PBMCs with iPSC-MSCs did not alter expression of CD25 or of NOTCH1 ([Supplemental Fig. S5, A](#SD6){ref-type="supplementary-material"} and [B](#SD6){ref-type="supplementary-material"}, respectively), although NOTCH1 levels also decreased by 72 h in co-culture.

The T cell-specific kinase, PKCθ, functions within a signal-amplifying cascade, to fully activate T cells ([@R22]) and promote tissue destruction in GvHD ([@R57]). To assess iPSC-MSC influence on PKCθ phosphorylation, we asked whether co-culturing iPSC-MSCs with PBMCs altered pPKCθ expression. iPSC-MSCs were left unlicensed or licensed with IFNγ for 48 h then co-cultured with stimulated PBMCs for an additional 96 h. We observed reduced expression of pPKCθ in PBMCs co-cultured with IFNγ-licensed, but not with unlicensed, iPSC-MSCs ([Fig. 1 F](#F1){ref-type="fig"}). In parallel, PD-1 levels also increased following co-culture with licensed, but not unlicensed iPSC-MSCs.

Collectively, these data show iPSC-MSCs phenotypically resemble native MSCs derived from BM and respond to IFNγ exposure in ways that are consistent with those of native MSCs, cultured under similar conditions. Furthermore, co-culturing with IFNγ-licensed iPSC-MSCs dampened the immune response of PBMCs, as measured by proliferation, expression of well-described activation and differentiation markers, and reduction of pro-inflammatory IFNγ, supporting the notion that iPSC-MSCs exert functional, immune-modulating actions, *in vitro*.

3.2.. iPSC-MSC administration, in vivo, reduces cytokine production and weight loss in mice with GvHD {#S15}
-----------------------------------------------------------------------------------------------------

Humanized mouse models have been used to evaluate the efficacy of MSC therapy to diminish disease severity ([@R45]). We utilized a lymphocyte transfer model of GvHD ([@R37]), in which human PBMCs are transferred into transgenic NOD.Cg-*Prkdc*^*scid*^ *Il2rg*^*tm1Wjl*^/SzJ (NSG) mice lacking T, B and NK cells, to investigate the therapeutic benefit of giving single or dual doses of iPSC-MSCs, under clinically-relevant conditions ([Supplemental Fig. S6](#SD7){ref-type="supplementary-material"}).

Before defining the *in vivo* therapeutic activity of iPSC-MSCs, we first verified that transferred PBMCs expanded to the same extent in iPSC-MSC-treated animals as they did in untreated GvHD controls. We found no differences in percentages of circulating PBMCs collected from untreated mice and from mice that received single- or dual-dose treatments of iPSC-MSCs ([Fig. 2A](#F2){ref-type="fig"}). Furthermore, percentages of circulating CD4 and CD8 T cells also did not differ significantly between treated and untreated animals ([Fig. 2, B](#F2){ref-type="fig"} and [C](#F2){ref-type="fig"}, respectively). These data are consistent with *in vitro* suppression data which showed only modest effects in co-culture ([Supplemental Table S1](#SD11){ref-type="supplementary-material"}), and with a previous report using a similar mouse model, and which demonstrated the protective effects afforded by MSCs are not due to accelerated elimination of disease-inducing PBMCs ([@R53]). We also confirmed that Cymerus iPSC-MSCs traffick, *in vivo*, in a manner consistent with BM-derived MSCs and what has been reported in the literature ([@R46]; [Supplemental Fig. S7A](#SD8){ref-type="supplementary-material"}--[F](#SD8){ref-type="supplementary-material"}). We labeled iPSC-MSCs and BM-derived MSCs with ^19^F or Alexa 488, administered both low (8 × 10^5^) and high (3 × 10^6^) doses of cells via injection through the tail vein, and assessed their biodistribution 24 h later using Nuclear Magnetic Resonance and immunofluorescence approaches. iPSC-MSCs and BM-derived MSCs migrated first to the lungs, then to the liver, although iPSC-MSCs appeared to exit from the lungs and infiltrate the liver with somewhat slower kinetics, compared to BM-derived MSCs ([Supplemental Fig. S7A](#SD8){ref-type="supplementary-material"}, [B](#SD8){ref-type="supplementary-material"}). We used histological and immunofluorescent staining of lung sections to visualize iPSC-MSCs as single cells (Alexa488-positive; [Supplemental Fig. S7C](#SD8){ref-type="supplementary-material"}, [D](#SD8){ref-type="supplementary-material"}, [F](#SD8){ref-type="supplementary-material"}), or as larger clusters of cells in which both Alexa488 and the human Ku80-specific antibody, STEM101, could be co-detected ([Supplemental Fig. S7C](#SD8){ref-type="supplementary-material"}, [E](#SD8){ref-type="supplementary-material"}, [F](#SD8){ref-type="supplementary-material"}). No MSCs were detected in animals beyond 7 days (data not shown), also consistent with previous reports ([@R48]). Altogether, these data suggest that Cymerus iPSC-MSCs and BM-derived MSCs traffick and persist similarly *in vivo*, following intravascular administration.

Pro-inflammatory cytokines released into the circulation during GvHD can cause significant weight loss in patients ([@R38]). In the pre-clinical model used here, high levels of circulating IFNγ correlate closely with disease severity ([@R37]). We monitored IFNγ levels, as well as changes in weight on day +19, for mice that were left untreated or were treated with single- or dual-doses of iPSC-MSCs. We observed significantly lower IFNγ in mice that received dual-doses of iPSC-MSCs, compared to untreated and to single-dose treated mice ([Fig. 2D](#F2){ref-type="fig"}). Reduced plasma cytokines correlated with significant relief from the cachexia-associated weight loss typically observed in this Th1-mediated model ([Fig. 2E](#F2){ref-type="fig"}). Although administering single or dual doses of iPSC-MSCs did not affect percentages of circulating PBMCs, compared to untreated GvHD control mice, the *in vivo* capacity of transferred PBMCs to produce proinflammatory cytokines was greatly diminished in mice that received dual doses of iPSC-MSCs.

3.3.. iPSC-MSC administration reduces BM-infiltration and expression of proinflammatory molecules in mice with GvHD {#S16}
-------------------------------------------------------------------------------------------------------------------

The mechanisms MSCs utilize to attenuate GvHD have not been fully elucidated, but reports suggest they influence immune cell activation and trafficking to target organs ([@R28]). The in vivo efficacy of human BM-derived MSCs varies greatly, both by donor and by *in vitro* expansion protocols. For these reasons, making a direct and useful treatment comparison between Cymerus iPSC-MSCs and donor-derived native MSCs is both challenging and arbitrary. Therefore, we induced GvHD in lightly-irradiated NSG mice, harvested blood and tissue samples +19 days after GvHD-induction, at the peak of disease, and evaluated target-tissue infiltration and markers of immune activation in untreated and in iPSC-MSC-treated mice. When we examined the BM, the major target of immune destruction in this model, we noted the percentages of BM-infiltrating PBMCs were significantly lower in mice given iPSC-MSCs, regardless of whether they received single or dual doses, compared to untreated controls ([Fig. 3A](#F3){ref-type="fig"}). We detected decreased BM-infiltration of CD4 ([Fig. 3B](#F3){ref-type="fig"}) and CD8 T cells ([Fig. 3C](#F3){ref-type="fig"},) which corresponded to higher total BM cellularity in iPSC-MSC-treated mice, compared to untreated GvHD control animals ([Fig. 3D](#F3){ref-type="fig"}). In contrast, percentages of human T cells in the spleen were less affected by iPSC-MSC-treatment ([Supplemental Fig. S8 A](#SD9){ref-type="supplementary-material"}--[C](#SD9){ref-type="supplementary-material"}). Thus, one means by which iPSC-MSCs may function *in vivo* in this model, is by protecting the BM from immune-mediated destruction caused by infiltrating PBMCs.

The lethal GvHD induced in this model is driven by CD4 Th1 and cytolytic CD8 T cells. We used flow cytometry to measure the expression of CD25, NOTCH1, and T-BET, to ask whether iPSC-MSC treatment attenuated this Th1-mediated response, *in vivo*. Except for CD25 expression on BM-infiltrating CD4 T cells, which did not differ between treatments ([Fig. 3E](#F3){ref-type="fig"}), there was significantly lower expression of all the pro-inflammatory markers evaluated on day +19. Compared to the levels expressed in untreated GvHD control animals, CD25 expression was lower on CD8 T cells recovered from the BM of iPSC-MSC-treated animals ([Fig. 3F](#F3){ref-type="fig"}). NOTCH1 ([Fig. 3, G](#F3){ref-type="fig"} and [H](#F3){ref-type="fig"}) and T-BET ([Fig. 3, I](#F3){ref-type="fig"} and [J](#F3){ref-type="fig"}), both of which are upregulated in Th1-mediated diseases ([@R34]; [@R44]), were also significantly decreased in BM CD4 and CD8 T cells from mice treated with single- or dual-dose regimens of iPSC-MSCs. Consistent with our *in vitro* co-culture results, we observed that treating animals with single- or dual-doses of iPSC-MSCs also significantly reduced expression of pPKCθ in CD4 and CD8 T cells recovered from the BM ([Fig. 3, K](#F3){ref-type="fig"} and [L](#F3){ref-type="fig"}; respectively).

Collectively, our data suggest iPSC-MSCs decrease the activation and infiltration of pro-inflammatory CD4 and CD8 T cells in the BM. We conclude that the reduced expression on PBMCs of multiple markers of activation, coupled with the low level of PKCθ phosphorylation, in BM-infiltrating CD4 and CD8 T cells, result from immune modulation mediated by iPSC-MSCs.

3.4.. iPSC-MSCs attenuate GvHD severity and prolong survival in mice {#S17}
--------------------------------------------------------------------

We assessed disease severity in our humanized model of GvHD, using a standardized scoring system ([@R37]), after randomly assigning mice to one of six treatment cohorts ([Supplemental Fig. S9 A](#SD10){ref-type="supplementary-material"}, [B](#SD10){ref-type="supplementary-material"}). Mice were humanely euthanized when they reached a cumulative score of "8" which was recorded as the day of lethal GvHD induction. We determined the survival benefit of administering iPSC-MSCs using Kaplan--Meier analyses with an applied log-rank test, with a *P* value of \< 0.05 considered significantly different.

Administering iPSC-MSCs significantly attenuated disease symptoms, compared to untreated mice ([Fig. 4A](#F4){ref-type="fig"}), and we noted further significant differences in clinical scores between single- and dual-dose treatments when we evaluated mice on days +24 and + 25 post-GvHD-induction. During survival studies, single- and dual-dose treatments conferred significant survival benefits over untreated GvHD controls (P \< .0001; [Fig. 4B](#F4){ref-type="fig"}). Animals receiving dual-dose regimens survived slightly longer (median = 57 days, range = 31--82 days) than single-dose-treated animals (median = 48 days, range = 33--60 days), although this difference was not statistically significant (*P* = .0715). Utilizing this pre-clinical model of GvHD, we conclude that administering single or dual doses of iPSC-MSCs, under clinically relevant conditions, significantly attenuates disease severity and conveys a robust survival benefit.

3.5.. iPSC-MSC-treatment alters subcellular localization of pPKCθ in BM-infiltrating T cells {#S18}
--------------------------------------------------------------------------------------------

One means by which protein activity can be regulated is through changes in subcellular compartmentalization ([@R3]). Dynamic redistribution of proteins between the cytosol and the nucleus may increase, decrease, or completely alter protein-protein interactions to differentially modulate biological outcomes ([@R11]). Indeed, a nuclear role for PKCθ has also been reported in human CD4 T cells, functioning as part of a complex that facilitates transcription of proinflammatory genes, including *IFNG* ([@R52]). To further understand, on a molecular level, the effects of treating mice with iPSC-MSCs, we asked whether the nuclear localization of pro-inflammatory proteins was altered following iPSC-MSC administration.

Using imaging flow cytometry, we analyzed the subcellular distribution of NOTCH1, T-BET, and pPKCθ, in BM-infiltrating CD4 and CD8 T cells from animals induced with GvHD and given single or dual doses of iPSC-MSC. Nuclear expression of NOTCH1 and T-BET in CD4 and CD8 T cells recovered from the BM was not significantly altered by iPSC-MSC treatment ([Supplemental Fig. S10, A](#SD2){ref-type="supplementary-material"}--[D](#SD2){ref-type="supplementary-material"}). In contrast, BM samples collected on day +19 from untreated animals with GvHD contained high percentages of nuclear pPKCθ-expressing CD4 and CD8 T cells. This nuclear localization of pPKCθ was confirmed by high positive nuclear similarity scores ([Fig. 5](#F5){ref-type="fig"}). However, the percentages of cells expressing nuclear pPKCθ were significantly lower, both in CD4 and CD8 T cells, in BM samples from mice treated with iPSC-MSCs ([Fig. 5, A](#F5){ref-type="fig"}, [B](#F5){ref-type="fig"}, [D](#F5){ref-type="fig"}, [E](#F5){ref-type="fig"}). Furthermore, the amount of pPKCθ detected in the nucleus, was also significantly reduced following treatment with iPSC-MSCs, both in CD4 and CD8 T cells ([Fig. 5, C](#F5){ref-type="fig"} and [F](#F5){ref-type="fig"}).

Altogether, these data indicate that, by day +19, a high percentage of T cells found in the BM express elevated levels of nuclear pPKCθ. Moreover, treating mice with iPSC-MSCs reduced the infiltration of nuclear pPKCθ-expressing T cells and, further, acted to diminish the amount nuclear pPKCθ within these CD4 and CD8 T cells.

3.6.. Pro-inflammatory molecules expressed by circulating PBMCs correlate with therapeutic response to iPSC-MSC administration {#S19}
------------------------------------------------------------------------------------------------------------------------------

A minimally-invasive means to identify biomarkers to predict or monitor therapeutic responses to iPSC-MSC administration would be of great clinical value. Therefore, we asked whether utilizing flow cytometry to analyze expression of pro-inflammatory markers on peripheral blood CD4 and CD8 T cells, found to be significantly different on BM-infiltrating immune cells, also correlated with disease severity. We measured expression of CD25 ([Fig. 6A](#F6){ref-type="fig"}, [B](#F6){ref-type="fig"}), NOTCH1 ([Fig. 6C](#F6){ref-type="fig"}, [D](#F6){ref-type="fig"}), T-BET ([Fig. 6E](#F6){ref-type="fig"}, [F](#F6){ref-type="fig"}), and pPKCθ ([Fig. 6G](#F6){ref-type="fig"}, [H](#F6){ref-type="fig"}) in circulating PBMCs from untreated and iPSC-MSC-treated mice, collected on day +19 after disease induction. Compared to PBMCs from untreated mice, the expression of all these pro-inflammatory molecules was significantly reduced as measured by the percent positive cells, the level of the proteins expressed, or both, following therapeutic administration of iPSC-MSCs.

Collectively, we demonstrate administering Cymerus iPSC-MSCs as a cell-based therapy provides relief from acute symptoms and significantly prolongs survival in a pre-clinical model of GvHD. Our data suggest iPSC-MSCs modulate PKCθ phosphorylation and subcellular localization. Furthermore, flow cytometric analysis of pro-inflammatory molecules may provide a set of biomarkers on circulating PBMCs that correlate closely with therapeutic response to iPSC-MSC administration.

4.. Discussion {#S20}
==============

Since the first experimental use of MSCs to successfully treat steroid-resistant GvHD ([@R26]) administering MSCs as a cell-based therapy has become an area of intensive investigation. However, inconsistent results in the clinic underscores all we do not yet understand about the precise mechanisms of action, the longevity of MSCs post-transfer, or even what contributes to the vast variability in performance between MSCs derived from different donors ([@R18]), all of which make a meaningful, direct comparison between Cymerus iPSC-MSCs and human BM-derived native MSCs difficult, if not impossible. While there are some indications cryopreserving MSCs adversely affects their immunosuppressive capacity ([@R40]; [@R17]), other reports suggest MSCs can undergo multiple passages or repeated freezing without exhibiting any diminished function ([@R31]). Extensive *ex vivo* expansion has been linked to telomere shortening in cultured MSCs ([@R4]), but whether this contributes to functional senescence and impaired efficacy, *in vivo*, is not known. Additionally, *in vitro* studies indicate senescence can be reversed by priming with IFNγ ([@R9]), but further studies are required to determine whether this phenomenon also occurs *in vivo*. One means to bypassing replicative senescence in MSCs may be to derive them from iPSCs ([@R47]). We show that iPSC-MSCs can be generated and expanded using a standardized protocol and Good Manufacturing Proce-dures, maintain their genetic stability, and display low levels of senescence immediately after thawing, which decreased over 48 h in culture, even without the addition of IFNγ. Furthermore, IFNγ licensing significantly increased IDO expression in iPSC-MSCs, consistent with the findings that IDO-mediated suppression is an important mechanism of immune modulation by MSCs ([@R9]). While we could not track the senescence of transferred iPSC-MSCs *in vivo*, the significant survival benefit noted following single- or dual-dose administration, indicate that iPSC-MSCs function for a sufficient length of time after infusion, to produce a durable immunomodulatory response.

Donor T cells traffic to secondary lymphoid organs within 24 h after HSCT ([@R2]). Following antigenic stimulation there, alloreactive CD4 and CD8 T cells expand and migrate to target tissues. In the humanized model of GvHD used in this study, the BM is the primary target organ, and mice die of lethal BM failure approximately three weeks after PBMC infusion. The accumulation of activated T cells in the BM of untreated mice, and the pro-inflammatory markers they express, are consistent with a Th1-mediated immune response, and one that will also drive effector functions of CD8 cytolytic T cells. This includes increased CD25 expression, upregulation of NOTCH1 and T-BET, and production of IFNγ, as well as sustained phosphorylation of the T cell-specific kinase, PKCθ, which is recruited to membrane lipid rafts following co-stimulation through the T cell receptor and CD28 ([@R25]). The high-affinity IL-2 receptor, CD25, is upregulated in activated T cells in a NOTCH1-dependent manner ([@R39]; [@R1]). Furthermore, physical association of NOTCH1 with PKCθ aids in assembly of the Carma1-BCL10-MALT1 supramolecular signaling complex in CD4 T cells, a prerequisite to activating the NF-κΒ (nuclear factor-κB) transcriptional complex ([@R50]).

PKCθ is one of nine members of the PKC family. It is required for mediating immune destruction in GvHD, identifying it as an attractive therapeutic target ([@R64]). However, close structural homology between PKCs make designing small molecule inhibitors to single isoforms challenging ([@R61]). Long-believed to be a cytosolic-resident kinase, a seminal study by [@R52] revealed a nuclear function for PKCθ in CD4 T cells, including positively regulating transcription of pro-inflammatory genes such as *IFNG*. We utilized imaging flow cytometry to evaluate the cellular localization of pPKCθ in BM-infiltrating CD4 and CD8 T cells. We found nuclear pPKCθ highly expressed in \> 80% of CD4 and CD8 T cells in the BM of untreated mice. By contrast, both the percentage of cells expressing nuclear pPKCθ, as well as the quantity of nuclear pPKCθ detected, was significantly reduced in CD4 and CD8 T cells collected from the BM of dual dose-treated animals. MSCs migrate to sites of inflammation, where the local concentration of IFNγ or TNF may be sufficient to license their immunomodulatory functions. iPSC-MSCs may be similarly recruited to the BM in this model of GvHD and exert immune suppressive effects on infiltrating T cells by reducing nuclear pPKCθ expression.

Alternatively, our data show that iPSC-MSCs may exit the lungs with slower kinetics than BM-derived MSCs. Recent reports suggest that interactions between MSCs and lung macrophages can modulate macrophage polarization, promoting an anti-inflammatory M2 phenotype, over the pro-inflammatory M1 state. This redirection of macrophage polarization may occur either as a result of macrophages directly engulfing MSCs ([@R6]) or through the paracrine effects of anti-inflammatory components secreted by the MSCs themselves ([@R35]). Macrophages are known to migrate to sites of inflammation. Therefore, it is possible that increased iPSC-MSC residence in the lungs may facilitate M2 polarization of lung macrophages, which then migrate to and infiltrate the BM, thus dampening immune destruction. However, further experimentation will be necessary to test this hypothesis.

Mechanistically, it is not entirely clear how iPSC-MSCs affect cytosolic *versus* nuclear distribution of pPKCθ. Surface expression of PD-L1 on iPSC-MSCs has the potential to interact with its cognate receptor PD-1, on activated CD4 and CD8 T cells. This interaction negatively regulates T cell activity by recruiting the phosphatase, SHP2, to surface micro-aggregates ([@R63]). Furthermore, it was recently demonstrated that SHP2 preferentially dephosphorylates CD28, within T cell receptor-CD28 signaling clusters ([@R21]). Given that PKCθ functions downstream of CD28 engagement ([@R20]), one means by which iPSC-MSCs may downregulate pPKCθ activity is through diminished CD28 signaling.

The immune modulator, IDO, also suppresses effector T cell functions, acting as the rate-limiting enzyme in the tryptophan catabolism pathway. IDO upregulation can suppress local tissue destruction during active GvHD ([@R23]). Mechanistically, limiting tryptophan availability has been shown to negatively regulate the AKT-mTOR pathway, as well as PKCθ phosphorylation ([@R33]). Gluco-kinase1 (GLK1), an amino acid-sensing molecule, phosphorylates PKCθ on threonine residue 538 following stimulation through the T cell receptor ([@R10]). In the absence of tryptophan, its kinase activity is limited, potentially impacting PKCθ phosphorylation. We noted robust expression of IDO by unlicensed iPSC-MSCs. This was further increased following exposure to IFNγ and co-culturing PBMCs with licensed iPSC-MSCs reduced PKCθ phosphorylation. Although numerous reports have correlated high IDO expression with potent MSC-mediated immune suppression, at least one report suggests that immune suppression can proceed in an IDO-independent manner, through PD-L1-PD1 signaling ([@R8]). Therefore, a distinct, or perhaps redundant, means by which licensed iPSC-MSCs may act to suppress T cells is through IDO-mediated regulation of tryptophan availability.

The benefits of using MSCs as a therapeutic modality are being explored for a variety of conditions, including end-stage chronic heart disease ([@R7]), ischemic stroke ([@R54]), acute myocardial infarct ([@R24]), kidney failure ([@R56]), and critical limb ischemia ([@R29]). Developing an efficacious MSC product to treat GvHD has been an important industry focus for several years. Products such as MSC-100-IV™ (Mesoblast, LLC), its Japanese-approved counterpart, Temcell® (JCR Pharmaceutical Co.; [@R30]), and Multistem® (Athersys, Inc.; [@R32]) are being evaluated in clinical trials. Common denominators for these products are that adult MSCs are collected from donors, pooled and expanded in culture, then cryopreserved until use. Cymerus iPSC-MSCs are unique in that they are derived from mesenchymoangioblasts, which are in turn derived from iPSCs. In addition to the fact that iPSCs can undergo nearly indefinite *ex vivo* expansion without losing pluripotency, mesenchymoangioblasts and their progeny also have enormous *ex vivo* expansion potential: cultures derived from a single mesenchymoangioblast have been shown to accumulate up to 10^22^ MSCs in total ([@R58]). Nonetheless, by primarily relying on expansion at the iPSC-level, extensive expansion of Cymerus iPSC-MSCs, post-differentiation, can be avoided. This approach facilitates the production of large numbers of Cymerus iPSC-MSCs from the same starting material, apparently without acquiring functional senescence or diminished immunosuppressive capacity *in vivo*.

5.. Conclusion {#S21}
==============

A thorough characterization of Cymeryus iPSC-MSCs reveals they mitigate signaling through the PKCθ pathway to attenuate GvHD progression. The exact mechanism by which this occurs will require further experimentation and is currently under active investigation in our lab. Additionally, having the ability to monitor patient response to iPSC-MSCs administration in real time, using a straight-forward, minimally-invasive flow cytometric analysis of pro-inflammatory markers expressed by circulating PBMCs, provides clinicians with valuable feedback upon which to make informed treatment decisions. Altogether, our data strongly support the use of Cymerus iPSC-MSCs as a treatment for GvHD, and its clinical efficacy is currently being studied in the context of a small, first-in-human trial for the treatment of steroid refractory GvHD.
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![iPSC-derived MSCs phenotypically resemble native MSCs, respond to IFNγ licensing, and dampen PBMC activation potential. iPSC-MSCs were plated as described; IFNγ was added to some cells. 24 or 48 h later, cells were harvested and stained with antibodies specific for (A) PD-L1 or (B) IDO. Cells were permeabilized prior to IDO staining. Data were acquired on a BD LSR Fortessa Flow Cytometer and analyzed using FlowJo software. For (C) *IDO* gene expression, cells were harvested after 24 or 48 h of culture with or without IFNγ.\
Total RNA was reverse transcribed, and *IDO* expression determined by quantitative real-time PCR using specific forward and reverse primers. For co-culture experiments, stimulated PBMCs were added to iPSC-MSCs and cultured an additional 24, 48, or 72 h. PBMCs were harvested and stained with antibodies specific for (D) T-BET. Percent positive cells and amount of protein expressed, indicated by median fluorescence intensity (MFI), was determined using flow cytometry. For some cultures, golgi plug was added during the last 6 h and (E) IFNγ levels were determined by intracellular staining and flow cytometric analysis. iPSC-MSCs were cultured without or with INFγ for 48 h. Stimulated PBMCs were added to iPSC-MSCs and cultured an additional 96 h. Expression of (F) pPKCθ was determined by immunoblotting. Loading control was β-actin. Data are the mean + SEM of three independent experiments or, for immunoblotting, are representative of two independent replicates that showed similar results. \*P \< .05; unpaired Student's t-test.](nihms-1522691-f0001){#F1}

![iPSC-MSC administration, *in vivo*, reduces cytokine production and weight loss in mice with GvHD. The percent of (A) human CD45 (B) human CD4 and (C) human CD8 positive PBMCs, was determined by flow cytometric analysis of peripheral blood samples from single- (*n* = 8) and dual-dose control (*n* = 8), GvHD control (*n* = 12), single- (*n* = 12) and dual-dose-treated mice (*n* = 12) harvested on day +19 after disease induction. (D) Circulating IFNγ was measured for cohorts of mice described in A, using standard ELISA techniques. (E) The percent weight change for cohorts of mice described in A was also determined. Data are the mean + SEM. \**P* ≤.05, \*\**P* \< .01, \*\*\**P* \< .001; unpaired Student's *t*-test.](nihms-1522691-f0002){#F2}

![iPSC-MSC administration reduces BM-infiltration and expression of proinflammatory molecules in mice with GvHD. The percent of (A) total human PBMCs, (B) human CD4 and (C) human CD8 T cells infiltrating the BM was determined by flow cytometric analysis of BM samples from single-(n = 8) and dual-dose control (*n* = 8), GvHD control (*n* = 12), single- (*n* = 12) and dual-dose-treated mice (*n* = 12) harvested on day +19 after disease induction. (D) Total BM cellularity was assessed for each of the cohorts of mice described. Flow cytometry was used to determine expression of (E, F) CD25, (G, H) NOTCH1, (I, J) T-BET, and (K, L) pPKCθ for populations of human CD4 (E, G, I, K, respectively) and human CD8 T cells (F, H, J, L, respectively) retrieved from the BM of untreated and treated mice with GvHD. Data are the mean + SEM. \**P* ≤ .05, \*\**P* \< .01, \*\*\**P* \< .001; unpaired Student's *t*-test.](nihms-1522691-f0003){#F3}

![iPSC-MSCs attenuate GvHD severity and prolong survival in mice. NOD.Cg-*Prkdc*^*scid*^ *Il2rg*^*tm1Wjl*^/SzJ (NSG) mice were conditioned with 2Gy of γ-irradiation from a ^137^Cs source. Control mice received only γ-irradiation (*n* = 8), a single (*n* = 8), or a dual dose of iPSC-MSCs (*n* = 8) without GvHD induction. Four hours after irradiation, GvHD was induced and mice were stratified into GvHD control, single- and dual-dose groups. The GvHD control group received no treatment (*n* = 12). For single-dose treatment (*n* = 12), mice received 2 × 10^6^ freshly-thawed iPSC-MSCs on day +14 after induction; for dual-dose treatment (n = 12), mice received 2 × 10^6^ freshly-thawed iPSC-MSCs on day +14 and on day +18 after induction. Clinical scores were generated based on standard criteria and mice were removed from the study when they reached a total score of "8". (A) Cumulative scores of mice in all treatment groups for the first 26 days of the study are shown. (B) Survival of mice with GvHD left untreated or treated was followed until they reached a score of "8" and were removed from the study. Significant differences between clinical scores were determined using two-way ANOVA and followed by Bonferroni post-test. Survival benefit of iPSC-MSC treatments was determined using Kaplan--Meier analysis with an applied log-rank test. \**P* ≤.05, \*\*\*\**P* \< .0001.](nihms-1522691-f0004){#F4}

![iPSC-MSC-treatment alters subcellular localization of pPKCθ in BM-infiltrating T cells. BM samples were collected on day +19 and single cell suspensions prepared. Cells were surface-stained for CD4 and CD8 expression with fluorescently-conjugated antibodies, fixed, permeabilized and stained intracellularly with fluorescently-conjugated antibodies specific for pPKCθ (Thr538). Nuclei were stained using cell-permeable DRAQ5™ fluorescent probe. Cells were visualized, nuclear pPKCθ was quantified, and nuclear similarity score was determined using an ImageStream^®X^ Mark II Imaging Flow Cytometer for BM-infiltrating (A--C) CD4 and (D--F) CD8 T cells. Subcellular localization of pPKCθ was determined using the Nuclear Localization Wizard and IDEAS® Software following masking of nuclear and non-nuclear regions. Images are representative of 12 mice analyzed for each cohort. Data are the mean + SEM. \**P* ≤ .05, \*\**P* \< .01, \*\*\**P* \< .001; unpaired Student's *t*-test.](nihms-1522691-f0005){#F5}

![Pro-inflammatory molecules expressed by circulating PBMCs correlate with therapeutic response to iPSC-MSC administration. Peripheral blood samples from GvHD control (*n* = 12), single- (*n* = 12) and dual-dose-treated (*n* = 12) mice were harvested on day +19 after disease induction. Flow cytometry was used to determine expression of (A, B) CD25, (C, D) NOTCH1, (E, F) T-BET, and (G, H) pPKCθ was determined for populations of human CD4 (A, C, E, G, respectively) and human CD8 T cells (B, D, F, H, respectively) in the circulation of untreated and treated mice with GvHD. Data are the mean + SEM. \**P* ≤.05, \*\**P* \< .01, \*\*\**P* \< .001; unpaired Student's *t*-test.](nihms-1522691-f0006){#F6}
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